Evaluation of the BBMEC model for screening the CNS permeability of drugs

被引:18
作者
Otis, KW
Avery, ML
Broward-Partin, SM
Hansen, DK
Behlow, HW
Scott, DO
Thompson, TN
机构
[1] Quintiles Inc, Kansas City, MO 64134 USA
[2] Pfizer Inc, Groton, CT 06340 USA
关键词
CNS permeability; in vitro model; blood brain barrier; transport study; P-glycoprotein;
D O I
10.1016/S1056-8719(01)00120-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Combinatorial synthesis and high-throughput pharmacology screening have greatly increased compound throughput in modem drug discovery programs. For CNS drugs, it is also important to determine permeability to the blood-brain barrier. Yet, given the increased pace of discovery, it difficult to conduct this screen in a timely fashion. In this presentation, we describe several improvements to an existing CNS permeability screen, the bovine brain microvessel endothelial cell (BBMEC) model. By implementation of these incremental process improvements, we have achieved a robust, facile screen for determination of CNS permeability of multiple compounds. (C) 2001 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:71 / 77
页数:7
相关论文
共 6 条
[1]  
Audus K L, 1996, Pharm Biotechnol, V8, P239
[2]   CHARACTERIZATION OF AN INVITRO BLOOD-BRAIN-BARRIER MODEL SYSTEM FOR STUDYING DRUG TRANSPORT AND METABOLISM [J].
AUDUS, KL ;
BORCHARDT, RT .
PHARMACEUTICAL RESEARCH, 1986, 3 (02) :81-87
[3]  
AVERY ML, 1999, 2000 ANN M AM ASS PH
[4]  
HANSEN DK, 2001, IN PRESS J PHARM BIO
[5]   Quantification of a potent 5-HT2a antagonist and an active metabolite in rat plasma and brain microdialysate by liquid chromatography - Tandem mass spectrometry [J].
Heath, TG ;
Scott, DO .
JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY, 1997, 8 (04) :371-379
[6]  
OTIS KW, 2000, ACS MED CHEM S KANS